RecruitingNCT07168616

Study of PSMA PET/CT Imaging to Help Select Men With Low-Risk Prostate Cancer for Active Surveillance

Prospective Evaluation of Istanbul PSMA PET/CT Criteria for Selecting Candidates for Active Surveillance in Low-Risk Prostate Cancer


Sponsor

Istanbul University - Cerrahpasa

Enrollment

201 participants

Start Date

Sep 1, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

This is a multicenter, prospective diagnostic accuracy study evaluating the Istanbul PSMA PET/CT Criteria (IPPC) for selecting patients with biopsy-confirmed low-risk prostate cancer (ISUP Grade 1) for active surveillance (AS). The study integrates delayed Ga-68 PSMA PET/CT imaging into the diagnostic pathway to refine patient stratification, minimize overtreatment and potentially reduce unnecessary biopsies and MRI, or exposing high-risk individuals to the danger of cancer progression if left untreated scans.


Eligibility

Sex: MALEMin Age: 18 Years

Inclusion Criteria9

  • mpMRI performed within 3 months prior to enrollment
  • Systematic or MRI-targeted prostate biopsy performed
  • Biopsy-confirmed ISUP Grade 1 low-risk PCa
  • Prostate biopsy report specifying tumor localization and number of positive cores
  • Meets AS criteria: ISUP 1, PSA ≤10 ng/mL, PSAd \>0.15 ng/mL², clinical stage cT1c-T2a, ≤3 positive cores
  • Life expectancy ≥10 years
  • No prior PSMA PET imaging
  • No evidence of extra-prostatic disease on mpMRI
  • Signed informed consent for study procedures

Exclusion Criteria7

  • High-risk or unfavorable intermediate-risk PCa, or adverse histologies (neuroendocrine, ductal adenocarcinoma, basal cell carcinoma, TP53 or BRCA1/2 mutations if available)
  • Prior prostate cancer treatment or prostate surgery
  • MRI evidence of extracapsular extension, seminal vesicle invasion, or nodal metastasis
  • History of pelvic radiotherapy
  • Life expectancy \<10 years
  • Severe renal impairment
  • Inability to comply with follow-up schedule

Interventions

DIAGNOSTIC_TESTGa-68 PSMA11 PET/CT

delayed (120-minute) Ga-68 PSMA PET/CT and will be evaluated by using Istanbul PSMA PET/CT Criteria (IPPC)


Locations(10)

Yeditepe University

Istanbul, Turkey, Turkey (Türkiye)

Bilkent Şehir Hastanesi

Ankara, Turkey (Türkiye)

Gazi Yaşargil Egitim ve Arastirma Hastanesi

Diyarbakır, Turkey (Türkiye)

Gaziantep Üniversitesi Şahinbey Araştırma ve Uygulama hastanesi

Gaziantep, Turkey (Türkiye)

Acibadem University Altunizade Hospital

Istanbul, Turkey (Türkiye)

Acibadem University Maslak Hospital

Istanbul, Turkey (Türkiye)

Haseki Eğitim ve Araştırma Hastanesi

Istanbul, Turkey (Türkiye)

Istanbul University-Cerrahpaşa

Istanbul, Turkey (Türkiye)

SBÜ Başakşehir Çam Sakura Şehir hastanesi

Istanbul, Turkey (Türkiye)

Sisli Hamidiye Etfal Eğitim ve Arastırma Hastanesi

Istanbul, Turkey (Türkiye)

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07168616


Related Trials